Sun Pharmaceuticals Industries Ltd News
USFDA rush after 2-year lull: 20-30% new products may be open to inspection_63067
The last two years saw limited physical inspections due to travel restrictions during the pandemic
 "USFDA rush after 2-year lull: 20-30% new products may be open to inspection_63067")
Sun Pharma's Halol unit gets 10 observations under USFDA's Form 483_61320
Plant's OAI status is unchanged, hinting at status quo; Sun Pharma says will respond to observations within 15 days
 "Sun Pharma's Halol unit gets 10 observations under USFDA's Form 483_61320")
Cipla, Ipca Lab, Zydus Life to benefit most from drug price rise: Analysts_48612
The recent price hike, analysts said, brings some respite for the industry facing multiple headwinds such as steep raw inflation, price erosion in the US market and higher freight costs.
 "Cipla, Ipca Lab, Zydus Life to benefit most from drug price rise: Analysts_48612")
Select pharma shares gain on tie-up for Pfizer Covid-19 oral treatment drug_45317
Among individual stocks, Aurobindo Pharma was the top gainer, which rallied 8 per cent to Rs 688.90 on the BSE in intra-day trade.
 "Select pharma shares gain on tie-up for Pfizer Covid-19 oral treatment drug_45317")
Here's why Vinay Rajani of HDFC Securities is bullish on GSFC, Sun Pharma_43841
The technical analyst expects the Nifty to turn bearish below 16,555; whereas on the upside sees resistance around 16,927 and 17,040 levels.
 "Here's why Vinay Rajani of HDFC Securities is bullish on GSFC, Sun Pharma_43841")
Sun Pharma rallies 8% in 2 days on heavy volumes; stock nears 52-week high_41298
Sun Pharma announced that its subsidiary Taro Pharmaceuticals USA Inc has completed the acquisition of subsidiary companies of Galderma
 "Sun Pharma rallies 8% in 2 days on heavy volumes; stock nears 52-week high_41298")
Top pharma firms to hike R&D spend next 5 yrs as mkt eyes $130 bn revenue_37092
Industry captains feel pandemic has opened up opportunities for the sector in India to emerge as a second source of raw material and finished products, after China
 "Top pharma firms to hike R&D spend next 5 yrs as mkt eyes $130 bn revenue_37092")
Stocks to Watch: Mahindra CIE, Dilip Buildcon, SIS, Butterfly Gandhimathi_35822
Stocks like Sun Pharma, Dr.Reddy's and others having exposure to Europe are likel to be in focus as the Russia-Ukraine crisis deepens.
 "Stocks to Watch: Mahindra CIE, Dilip Buildcon, SIS, Butterfly Gandhimathi_35822")
Sun Pharma hits six year-high; gains 13% in last eight days on strong Q3_27612
In Q3, the company has witnessed stronger growth than anticipated in the US, Emerging Markets and RoW.
Sun Pharma rallies 5%, hits new 52-week high post Q3 results_25807
The management said the company achieved a sustained momentum and good growth across businesses; despite rising costs, achieved higher profitability.
Sun Pharma Q3 results: Net profit rises 11% to Rs 2,058.8 crore_25681
In Q3, the revenue from specialty products came in at $183 million, up 21 per cent YoY
 "Sun Pharma Q3 results: Net profit rises 11% to Rs 2,058.8 crore_25681")
Sun Pharma Q3 results: Net profit rises 11% to Rs 2,059 cr_25435
Total revenue from operations rose to Rs 9,863 cr in the third quarter as compared to Rs 8,836.7 cr in the same period of previous fiscal
 "Sun Pharma Q3 results: Net profit rises 11% to Rs 2,059 cr_25435")
Sun Pharma-arm Taro logs better-than-expected Q3 Ebitda margin; stock up 4%_24414
In Q3FY22, Taro's EBITDA margins improved 108 bps year-on-year (YoY) to 31.3 per cent mainly due to better gross margins.
Bharti Airtel, L&T, M&M among top trading bets ahead of Budget 2022_20234
Major stocks have broken out on upside, any trigger in Budget 2022 could see sharp up move
 "Bharti Airtel, L&T, M&M among top trading bets ahead of Budget 2022_20234")
Sun Pharma gains 4% on earnings optimism, stock scales a 5-year high_18376
The better traction in the specialty segment and improvement in domestic business to drive the margin expansion in Q3.
 "Sun Pharma gains 4% on earnings optimism, stock scales a 5-year high_18376")
Bulls in-charge: Over 50% stocks from Nifty500 trade above major support_14793
Stocks like Asian Paints, Astral, Balrampur Chini, Birlasoft, Carborundum Universal, eClerx, Infosys, Max Healthcare, Tube Investments and Torrent Pharma and others are trading at life-time highs
 "Bulls in-charge: Over 50% stocks from Nifty500 trade above major support_14793")
Sun Pharma, TCS, UltraTech: 5 Sensex stocks that you should bet on for 2022_13537
Year 2020 may see up to 20 per cent jump in these stocks, as the chart formations reveal higher interest of market players in these counters
 "Sun Pharma, TCS, UltraTech: 5 Sensex stocks that you should bet on for 2022_13537")
Sun Pharma expected to shine on domestic prospects, US sales ramp up_12832
Anti-covid drug approval, new facility are the near term triggers for the pharma firm's stock
Pharma shares trade firm; Laurus up 2%, Sun Pharma nears 52-week high_12610
Sun Pharma, Cipla, Natco, Dr Reddy's, Torrent Pharma, Aurobindo Pharma and Strides have launched a generic version of Molnupiravir in India post approval for emergency use authorisation from DCGI
 "Pharma shares trade firm; Laurus up 2%, Sun Pharma nears 52-week high_12610")
RIL, HCL Tech: These 7 oversold stocks are set to lead market recovery_9569
The underneath strength, preferably read as price action, has been able to hold ground around the major neckline supports for these stocks
 "RIL, HCL Tech: These 7 oversold stocks are set to lead market recovery_9569")
